Literature DB >> 16493071

Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes.

Lanfen Chen1, Celia F Brosnan.   

Abstract

The purinergic receptor P2X7R is a nucleotide-gated ion channel that has been proposed to function as a major regulator of inflammation. In this study we examined the role of this receptor in regulating inflammation in the CNS by determining the effects of the loss of this receptor (P2X7R-/-) on experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. We show here that P2X7R-/- mice developed more severe clinical and pathological expression of EAE than wild type (WT) controls and that spleen and lymph node cells from P2X7R-/- mice proliferated more vigorously to Ag in vitro. Bone marrow (BM) radiation chimeras revealed that enhanced susceptibility to EAE was detected in chimeric mice of WT host engrafted with P2X7R-/- BM cells, indicating that the genotype of the BM cells regulated disease susceptibility. Coculture of P2X7R-/- macrophages with WT lymphocytes and vice versa showed that enhanced proliferative activity resided within the P2X7R-/- lymphocyte population and correlated with reduced levels of IFN-gamma and NO and apoptosis of lymphocytes. mRNA and protein for IFN-gamma were also significantly reduced in the CNS of P2X7R-/- mice with EAE. FACS analysis of cells isolated from the CNS showed significantly fewer annexin V/propidium iodide-positive lymphocytes in the CNS of P2X7R-/- mice early in the disease, and TUNEL staining of inflamed CNS tissues supported this result. From these data we conclude that enhanced susceptibility of P2X7R-/- mice to EAE reflects a loss of apoptotic activity in lymphocytes, supporting an important role for this receptor in lymphocyte homeostasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493071     DOI: 10.4049/jimmunol.176.5.3115

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 2.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

Review 3.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

4.  Physiological and pathological functions of P2X7 receptor in the spinal cord.

Authors:  Maria Luisa Cotrina; Maiken Nedergaard
Journal:  Purinergic Signal       Date:  2009-02-11       Impact factor: 3.765

Review 5.  P2X7 receptors in oligodendrocytes: a novel target for neuroprotection.

Authors:  Carlos Matute
Journal:  Mol Neurobiol       Date:  2008-08-14       Impact factor: 5.590

Review 6.  Neuronal P2X7 Receptors Revisited: Do They Really Exist?

Authors:  Peter Illes; Tahir Muhammad Khan; Patrizia Rubini
Journal:  J Neurosci       Date:  2017-07-26       Impact factor: 6.167

Review 7.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

8.  Diadenosine homodinucleotide products of ADP-ribosyl cyclases behave as modulators of the purinergic receptor P2X7.

Authors:  Santina Bruzzone; Giovanna Basile; Madhu Parakkottil Chothi; Lucilla Nobbio; Cesare Usai; Emanuela Jacchetti; Angelo Schenone; Andreas H Guse; Francesco Di Virgilio; Antonio De Flora; Elena Zocchi
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

9.  VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown.

Authors:  Azeb Tadesse Argaw; Blake T Gurfein; Yueting Zhang; Andleeb Zameer; Gareth R John
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

Review 10.  Purinergic signaling in oligodendrocyte development and function.

Authors:  Taylor G Welsh; Sarah Kucenas
Journal:  J Neurochem       Date:  2018-03-25       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.